期刊论文详细信息
Journal of Cellular and Molecular Medicine | |
CELF2 is a candidate prognostic and immunotherapy biomarker in triple‐negative breast cancer and lung squamous cell carcinoma: A pan‐cancer analysis | |
Chunguang Guo1  Long Liu2  Yuling Sun3  Libo Wang3  Dechao Jiao4  Zaoqu Liu4  Xinwei Han4  Lifeng Li5  Jie Zhao6  | |
[1] Department of Endovascular Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China;Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China;Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China;Institute of Hepatobiliary and Pancreatic Diseases, Zhengzhou University, Zhengzhou, China;Zhengzhou Basic and Clinical Key Laboratory of Hepatopancreatobiliary Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China;Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China;Internet Medical and System Applications of National Engineering Laboratory, Zhengzhou, China;Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China;Internet Medical and System Applications of National Engineering Laboratory, Zhengzhou, China;Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; | |
关键词: CELF2; immune infiltration; immunotherapy; lung squamous cell carcinoma; prognosis; triple‐negative breast cancer; | |
DOI : 10.1111/jcmm.16791 | |
来源: Wiley | |